Patents by Inventor DAVID EAVARONE
DAVID EAVARONE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002537Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: November 7, 2022Publication date: January 4, 2024Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20240003889Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.Type: ApplicationFiled: November 7, 2022Publication date: January 4, 2024Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20240000962Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: November 7, 2022Publication date: January 4, 2024Applicant: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20230331868Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: ApplicationFiled: June 14, 2023Publication date: October 19, 2023Applicant: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Publication number: 20230312747Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.Type: ApplicationFiled: December 6, 2022Publication date: October 5, 2023Applicant: Seagen Inc.Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
-
Publication number: 20230142697Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.Type: ApplicationFiled: June 22, 2022Publication date: May 11, 2023Applicant: Seagen Inc.Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
-
Publication number: 20230022411Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.Type: ApplicationFiled: March 16, 2022Publication date: January 26, 2023Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20230029085Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: March 16, 2022Publication date: January 26, 2023Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20230001007Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: January 4, 2022Publication date: January 5, 2023Applicant: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20220259323Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: ApplicationFiled: December 1, 2021Publication date: August 18, 2022Applicant: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Patent number: 11401330Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.Type: GrantFiled: November 17, 2017Date of Patent: August 2, 2022Assignee: Seagen Inc.Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
-
Publication number: 20220057402Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: May 26, 2021Publication date: February 24, 2022Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Patent number: 11253609Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: GrantFiled: March 2, 2018Date of Patent: February 22, 2022Assignee: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Patent number: 11028181Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: GrantFiled: November 10, 2016Date of Patent: June 8, 2021Assignee: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Publication number: 20210011021Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: February 14, 2020Publication date: January 14, 2021Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Publication number: 20200247902Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.Type: ApplicationFiled: November 17, 2017Publication date: August 6, 2020Applicant: Seattle Genetics, Inc.Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
-
Publication number: 20200041517Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.Type: ApplicationFiled: June 10, 2016Publication date: February 6, 2020Applicants: Seattle Genetics, Inc., The General Hospital CorporationInventors: David A. EAVARONE, Julie DeSANDER, Jeffrey BEHRENS, Bo R. RUEDA, Rosemary FOSTER, Kristen D. STARBUCK
-
Publication number: 20200000932Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: March 2, 2018Publication date: January 2, 2020Applicant: SEATTLE GENETICS, INC.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20190276541Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.Type: ApplicationFiled: November 17, 2017Publication date: September 12, 2019Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
-
Publication number: 20190031780Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: January 27, 2017Publication date: January 31, 2019Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
